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SUMMARY
Aims: As major depression (MD) is often comorbid with alcohol-use disorders (AUD) and
alcohol itself modulates the immune system, we examined serum levels of interleukin
(IL)-6, IL-10, tumor necrosis factor (TNF), and interferon (IFN)-c in AUD patients with and
without MD. Putative interactions between alcohol variables and MD on cytokine levels
were also assessed.Methods: A consecutive sample of inpatients with AUD (N = 176) from
eight alcohol treatment centers in Kathmandu, Nepal, was assessed for alcohol use and
depression by administering fully structured psychiatric interviews. Serum cytokine levels
were determined using multiplex technology. Results: Alcohol-use disorders patients with
a positive history of MD had higher levels of the inflammatory cytokines IL-6 (P = 0.019),
TNF (P = 0.020), and IFN-c (P = 0.001), but not of IL-10 (P = 0.853). AUD patients with
MD had higher concentrations of cytokines compared with those without, regardless of the
severity of the alcohol problem, but the difference was greater among those drinking in
lower frequency and intensity. Conclusion: These findings provide evidence for altered
functioning of the immune system in AUD patients with comorbid MD. However, frequent
and intense drinking may attenuate the difference in the cytokine profiles between AUD
patients with and without MD.
Introduction
Major depression (MD) is a highly prevalent and potentially debil-
itating psychiatric illness characterized by sustained depression of
mood, anhedonia, significant changes in weight, psychomotor
disturbance, fatigue, inability to concentrate, inappropriate guilt,
as well as recurrent thoughts of death [1,2]. Recent advances in
psychoneuroimmunology have demonstrated that about a third
of depressed individuals exhibit activated inflammatory responses
as measured by increased circulating levels of inflammatory
cytokines such as interleukin-6 (IL-6), tumor necrosis factor
(TNF), and interferon gamma (IFN-c) [3–5]. It has been postulated
that the activation of these inflammatory mediators directly con-
tributes to the development of depressive disorders [6]. Evidence
shows enhanced inflammation can provoke a depressive episode
[7], cause depressive symptoms as happens with IFN-a-based
immunotherapy [8], drive an ongoing depressive state or modu-
late the severity of depressive symptoms [9], and persist after clini-
cal recovery [10].
Approximately 30% of patients with MD will satisfy a DSM-
IV-TR diagnosis of alcohol-use disorder (AUD: alcohol abuse or
alcohol dependence) in their lifetime [11]. Even higher preva-
lence of MD is reported among patients with AUD in different
populations [12–14]. For example, 45% of Nepalese inpatients
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with AUD would satisfy a lifetime diagnosis of major depressive
episode [15].
Alcohol modulation of the immune function has been evi-
denced by altered levels of various cytokines in plasma, liver,
lungs, and brain samples in patients with AUD [16,17]. While
acute and moderate use of alcohol has been associated with
down-regulated inflammatory responses characterized by inhib-
ited TNF and IL-6 and augmented IL-10 production, chronic
heavy alcohol use results in increased inflammatory responses
[18]. Although reports in the literature vary according to the cyto-
kine studied, the severity of alcohol problems, and hepatic dam-
age, it is clear that alcohol-use disorders result in dysregulated
cytokine balance [19].
Given the individual effect of alcohol use and depression on
immune function and the frequent comorbidity between AUD
and MD, the effect of comorbidity on immune function as a
common underlying biological mechanism requires further
investigation. Relatively few studies have examined immune
activation among alcohol-dependent individuals; even fewer
have made direct comparisons between AUD patients with and
without depression. Furthermore, the few studies that have
made such comparisons lacked measurements of circulating
cytokines and had small sample sizes (<100). Using ex vivo mea-
sures of immune cell function, Schleifer et al. [20] observed that
enumerative and functional immune changes associated with
depression among patients with AUD were consistent with those
seen in depression alone. The authors also identified associations
between attributes such as smoking and recency of alcohol
intake with immune changes in alcohol use and, more mod-
estly, in depression. Relatedly, other studies have identified eth-
nic and socio-demographic differences in the circulating
cytokine profile of people with depression and alcohol misuse in
both clinical and community samples [21,22]. Thus, it is impor-
tant to include relevant behavioral attributes and to examine
populations from diverse settings in studies of the theoretical
underpinnings of the relationship between AUD, depression,
and inflammation.
We hypothesized that MD comorbid with AUD would result in
further increases of the inflammatory cytokines and that alcohol
severity would relate directly to their levels. To study this hypoth-
esis, we measured serum levels of four cytokines that have been
related to immunodysregulation in these disorders (i.e., IL-6,
IL-10, TNF, and IFN-c), in a Nepalese sample of AUD inpatients
with and without MD.
Materials and methods
Recruitment Procedure and Data Collection
This article is based on cross-sectional data of Nepalese patients in
eight alcohol treatment centers in Kathmandu, Nepal. All institu-
tions but one used a 12-step-based rehabilitation program for
recovery. The study’s general methodology has been described
previously [15]. Participants were free from alcohol for at least
4 days before the collection of blood samples, and psychiatric
interviews were held at least 10 days after enrollment into treat-
ment. The study protocol was approved by the relevant Norwe-
gian and Nepalese ethics committees prior to data collection.
We approached 221 consecutively admitted clients, explained
the study procedure and invited them to participate. After screen-
ing for inclusion, 204 eligible participants provided written
informed consent (thumb print with witness’s signature from illit-
erate clients) together with a separate consent for collection of a
blood sample. There were 188 patients who satisfied the DSM-
IV-TR criteria for an alcohol-use disorder (24 alcohol abuse and
164 alcohol dependence); 11 participants refused to offer blood
samples. The study comprised of the remaining 176 patients with
AUD.
A general physical examination was carried out, and about
8 mL of antecubital venous blood was collected on a BD vacutain-
er gel tube in the late afternoon. Within 2.5 h of sampling, the
serum was separated on a swing-out centrifuge (1300 9 g) at
room temperature and transferred into a polypropylene tube,
which was then stored at 70°C. Using solidified carbon dioxide,
the frozen samples were transported to the research laboratory at
Nordland Hospital in Bodø, Norway, where the cytokine assays
were performed.
Questionnaires
Psychometric evaluation was performed using the World Health
Organization’s second version of the Composite Interview Diag-
nostic Interview (CIDI; WHO, 1994) administered in the local lan-
guage. The DSM-IV-TR diagnoses of alcohol-use disorders (305.00
alcohol abuse or 303.90 alcohol dependence) and major depres-
sive episodes (MD) were obtained from the CIDI. Patients were
asked to denote the time at which the cardinal symptoms of MD
appeared and lasted for at least 2 weeks, excluding recent com-
plaints. A modified version of the demographic module of the
CIDI was used to record the variables gender (female/male), place
of residence (rural/urban), educational level (illiterate or primary/
higher), marital status (married/other), caste category (high/low),
employment (regular income source/other), and social support
(inadequate/adequate). Alcohol-use parameters were measured
using the Alcohol Use Disorder Identification Test (AUDIT) [23].
We also administered the Hopkins Symptoms Checklist- 25
(HSCL-25) [24] to evaluate psychological distress in the last
15 days that would capture transient mood alterations in the
recently detoxified AUD sample. Recent distress was defined as
average HSCL-25 score of 1.75 or higher in both genders. The
instruments have shown acceptable reliability and were locally or
regionally validated, and their translated Nepali versions have
been used previously [25–27].
Determination of Cytokine Levels
Serum levels of the three inflammatory cytokines IL-6, TNF, and
IFN-c, and an anti-inflammatory cytokine IL-10 were assayed by
a multiplex cytokine assay (Human Bio-Plex; Bio-Rad Laborato-
ries Inc., Hercules, CA, USA) according to instructions from the
manufacturer. The interassay and intraassay coefficients of varia-
tion were <10% for all analyses. All values were within the stan-
dard curve, except for two extreme outliers for TNF, which were
excluded. Additionally, serum levels of gamma-glutamyl transfer-
ase (c-GT), a general marker for liver injury, and carbohydrate
deficient transferrin (CDT), a useful marker for recent alcohol
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consumption, were determined using standard photometry and
capillary electrophoresis, respectively.
Statistical Analysis
SPSS version 20 for Windows (SPSS Inc., Chicago, IL, USA)
was used for the statistical analysis of the data. Descriptive
statistics are presented as percentages, means, and standard
deviations. The association between demographics and MD
diagnosis was observed by Pearson’s chi square-test. The spread
of the cytokine values were rather skewed and therefore
reported by categories of alcohol variables as medians and 25/
75 percentiles. Their distributions across no-MD and MD groups
are shown in boxplots.
The nonparametric Mann–Whitney U-test was used to observe
differences in cytokine concentrations according to demographic
and alcohol-use parameters. For ease of presentation, weekly fre-
quency of alcohol use, ethanol consumed per drinking day, and
abstinence duration were dichotomized at 4 days, 10 standard
units, and 10 days, respectively. Spearman’s correlation was used
for estimating correlations between cytokines and other continu-
ous variables. Finally, the role of alcohol variables in the relation-
ship between MD and cytokines is depicted as bar diagrams. All
tests were two-tailed with the statistical significance set at 5%
level.
Results
Patient Characteristics and Cytokine Profile
The study sample had a mean age of 35.5 (10.2) years with a
history of habitual drinking of alcohol for 16.9 (10.0) years
and abstinence from alcohol for 33.8 (22.5) days prior to
interview. As many as 78% of the current sample had a total
AUDIT score of above 20 (mean 27.9 [SD 8.7]), which accord-
ing to WHO indicates high likelihood for meeting alcohol
dependence diagnosis. It consisted predominantly of males
(89%) and urban residents (69%). Table 1 lists the socio-demo-
graphic and clinical characteristics of the sample by depression
history. Compared with the group that reported no history of
MD, MD patients (n = 80, 45% including 36% who had MD in
the 12-months preceding assessment) were less likely to be co-
habitating or to have a regular source of income. The two
groups did not vary by the duration, frequency and extent of
alcohol use, abstention duration in current treatment, or recent
medication (Table 1).
There were no significant differences in cytokine levels across
socio-demographic variables, such as, gender, age group, marital
status, education, income level, place of residence, and social
support or the month of sampling (data not shown).
Serum Cytokine Levels in Depression
We first compared cytokine levels in AUD patients with and with-
out a history of MD. The MD group had increased levels of the
inflammatory cytokines IL-6 (P = 0.019), TNF (P = 0.020), and
IFN-c (P = 0.001), but not of IL-10 (P = 0.853) compared with
the no-MD group (Figure 1). Satisfying an MD diagnosis in the
preceding 12-month period showed results similar to lifetime MD,
but recent distress was not related to higher cytokine levels. In
fact, MD patients without recent psychological distress had signifi-
cantly higher levels of TNF (P = 0.012) and IFN-c (P = 0.001)
compared with non-MD patients without psychological distress.
This difference was not seen in recent distress.
Alcohol-related Measures
Some alcohol-use variables were related to cytokine levels
(Table 2). High-frequency drinking (≥4 days per week) was
related to higher serum IFN-c (P = 0.026) and IL-10 (P = 0.005)
levels compared with the group who drank less frequently. Simi-
larly, drinking 10 or more standard units of alcohol on a typical
day was related to higher IL-10 (P = 0.024) levels compared with
drinking moderately. The cytokines did not differ across categories
of AUD (alcohol abuse and alcohol dependence) and abstinence
duration (below 10 days and above; Table 2). None of the studied
cytokines correlated significantly with c-GT and CDT levels. Abus-
ing an illicit substance in the preceding year did not influence
cytokine levels (P > 0.05 for all cytokines). However, current
smoking was associated with lower IL-6 level, particularly in the
MD group (P = 0.010).
Interaction between Alcohol and Depression
Measures
The interaction between alcohol and depression measures is
shown in Figure 2. Generally, AUD patients with a positive his-
tory of MD tended to have higher concentrations of cytokines
Table 1 Demographic and medical characteristics of alcohol-use
disorder inpatients (N = 176) in Nepalese alcohol treatment centers by






P-value*n % n %
Gender: Male 87 91 69 86 0.475
Residence: Urban 33 34 22 28 0.414
Education: illiterate or primary
level (vs. higher)
31 32 21 26 0.411
Marital status: married 69 72 40 50 0.003
Hindu caste: high 53 55 43 54 0.880
Employment: regular source
of income
65 68 39 49 0.009
Social support: adequate 70 73 55 69 0.617
Institution: rehabilitation
center (vs. hospital)
82 85 70 88 0.826
Medication: any use in the past week 31 32 33 41 0.271
Drinking frequency: ≥4 days weekly 69 73 61 77 0.600
Daily drinking units: average ≥10 units 63 76 56 74 0.850
No MD and MD cases for some variables may not sum to 176 due to
missing data. *P-value for the difference between never depressed and
ever depressed group, by chi square-test. Significant values are shown
in bold.
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compared with those without MD, regardless of the severity of
alcohol problems. Compared with patients without a history of
major depression, MD patients who used alcohol 3 days or fewer
per week in quantities below 10 standard units had significantly
higher IL-6, TNF, IFN-c, and IL-10 levels. However, this associa-
tion was attenuated in the groups who drank with higher fre-
quency and intensity. Abstinence duration dichotomized at
10 days did not show a clear trend. Nonetheless, levels of IL-6 and
IFN-c were higher among MD patients with more than 10 days of
abstinence.
Discussion
This cross-sectional study from Nepal investigated the relationship
between MD and cytokines specifically in alcohol-use disorder
(AUD) patients. Patients with comorbid MD showed increased
levels of the inflammatory cytokines IL-6, TNF, and IFN-c relative
to the AUD patients without MD comorbidity, replicating earlier
findings from non-AUD populations [3,4]. The impact of MD on
immune responses was strong in AUD patients with less heavy
alcohol use (i.e., drinking with lower frequency and amounts, and
satisfying fewer symptoms of AUD), and these patients also
showed increased IL-10 levels. Patients with more heavy alcohol
use; however, had a nonsignificant difference in cytokine levels
between MD and non-MD groups. This indicates that heavy alco-
hol use may attenuate the difference in cytokine profiles between
AUD patients with and without MD. Thus, our findings lend sup-
port to the hypothesis that AUD and MD interact in a complex
manner and that immune mechanism may be a connecting piece
of the puzzle [28].
Patients with MD as a comorbidity have been found to have
raised plasma and serum levels of inflammatory markers as
compared with patients without this comorbidity in a multitude
of medical conditions, including cardiovascular disease [29],
multiple sclerosis [30], cancer [31], and fibromyalgia [32].
Patients with addiction problems are important groups to con-
sider in this context because of the high rates of comorbidity
with MD with potential impact on immunity. Patients with
AUD are of particular interest as alcohol itself acts as a modula-
tor of the immune system, and its chronic use has been reliably
demonstrated to activate both innate and adaptive immunity
[17,18]. However; unlike in depression disorders, immune
alterations in alcohol use have been less clear and often linked
to associated medical morbidities, liver damage, and smoking
status [33]. The cytokine response in AUD could potentially
reflect liver damage, but in this study, we found no association
between cytokine levels and c-GT, a general marker of alcohol-
induced liver disease. Neither was the marker for recent alcohol
use (CDT) related to the cytokine levels. Smoking history,
nonetheless, was associated with cytokine alterations. Patients
with MD as a comorbidity had increased serum levels of IL-6,
TNF, and IFN-c, but not IL-10 as compared to those without
MD, suggesting an enhanced inflammatory phenotype in
patients with the co-existence of AUD and MD. We also found
that the association between inflammatory cytokines and
depression among people with AUD was less obscure when life-
time prevalence was considered as opposed to past-year major
depressive episodes or recent distress. This may reflect that the
inflammatory subset of depression in AUD is also pervasive as
a trait ingredient of the comorbidity and in a lesser degree, a
time-dependent association in relation to recent depressive epi-
sodes. Indeed, some evidence supports the lingering nature of
immune activation in depressive disorders [10,34]. These issues
as well as whether the increased inflammatory markers predict
future episodes of depression in AUD should be explored with
prospective studies. If cytokine profiles or changes in profiles
are consistently observed in longitudinal studies to influence
the onset or remission of depression in AUD, interventions tar-
geting immune function may be effective and should be devel-
oped and tested.
Figure 1 Boxplot showing median (central
lines), 25% and 75% quartile ranges around the
median (box width), and upper and lower limits
(whiskers) of serum levels of interleukin-6 (IL-6),
tumor necrosis factor (TNF), interferon gamma
(IFN-c), and IL-10 in alcohol-use disorder
patients reporting no history of lifetime major
depression (no MD, n = 96) or reporting a
lifetime history of major depression (MD,
n = 80). P-values were calculated by Mann–
Whitney U-test.
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In AUD patients with heavy alcohol use, the impact of MD on
cytokine levels was attenuated. Moreover, patients with a higher
frequency of alcohol intake (≥4 days per week) had higher IFN-c
levels than the other individuals with AUD. The bulk of the litera-
ture on alcohol-induced immune activation is based on experi-
ments in animal models and in vitro studies. Based on such
studies, it has been suggested that regulation of inflammatory
cytokine production by monocyte and macrophage seems to be
depending on the length of alcohol treatment [17]. Our findings
in this study suggest that proxy measures of AUD severity, such as
ethanol intake with high frequency and intensity, may influence
the cytokine levels in serum. In heavy drinkers, this may be the
dominant factor in relation to inflammation even in patients with
accompanying MD. In those drinking with lower frequency and
amounts, further increased levels of inflammatory cytokines in
MD (compared with the more heavy drinkers) may be the result
of reduced tryptophan and increased kynurenine levels, as evi-
denced in short-term alcohol exposure in humans [35]. This issue
and how alcohol abuse in terms of frequency, quantity, and type
of beverage impacts on the cytokine and T-cell homeostasis merit
further investigation.
The anti-inflammatory cytokine IL-10 did not vary significantly
between groups with and without MD. In contrast, high levels of
alcohol-use were significantly related to circulatory IL-10 levels.
Thus, drinking ≥10 units of pure alcohol on a typical day and
drinking ≥4 days per week were both associated with high IL-10
level. It may be that IL-10-mediated anti-inflammatory responses
in conjunction with increased IL-6 levels reflect activation of the
Th2 T-cell subset in these patients [36]. Hence, although
decreased IL-10 responses have been associated with alcohol-
induced liver disease, our findings suggest that severe alcohol
abuse may be associated with increased IL-10, at least in the con-
text of accompanying MD. This could potentially promote immu-
nosuppression in these individuals.
We acknowledge some limitations to our study. Because of
the cross-sectional nature of the study, without a control sample,
we are unable to draw a conclusion about whether the increase
in the levels of cytokines was actually associated with the disor-
ders considered and not featured artifacts of other inflammatory
processes in these patients. We did not observe any variation in
our findings of cytokine difference across MD and alcohol char-
acteristics according to gender or type of treatment being
received. However, it is important to control for antidepressant
and anti-inflammatory medications, as these can clearly con-
found the results [37]. Moreover, serum levels may not neces-
sarily reflect the levels within the microenvironment such as the
brain. In spite of these limitations, this study provides important
immunological insights into the complex interactions between
the frequently comorbid conditions of alcohol and depression
disorders.
In conclusion, the results from this study suggest that a treat-
ment sample of alcohol-use disorder patients with positive history
of major depression has increased levels of circulatory IL-6, TNF,
and IFN-c, but not of IL-10. However, these differences seem to
attenuate in heavy alcohol use. Prospective, controlled studies are
needed to confirm the role of alcohol in the relationship between
depression and immunity, vis-a-vis the potential role of cytokines






















































































































































































































































































































































































































































































































































































































































































































902 CNS Neuroscience & Therapeutics 20 (2014) 898–904 ª 2014 John Wiley & Sons Ltd
Cytokines in AUD-MD Comorbidity S.P. Neupane et al.
Acknowledgments
The authors would like to thank the treatment centers and their
clients for their participation in this research.
Conflict of Interest
The authors declare no conflict of interest.
References
1. Mathers C, Fat DM, Boerma JT. The global burden of disease:
2004 update. Zeneva: World Health Organization, 2008.
2. American Psychiatric Association. Diagnostic and
statistical manual of mental disorders, 5th edn. Washington,
DC: American Psychiatric Association, 2013.
3. Dowlati Y, Herrmann N, Swardfager W, et al. A
meta-analysis of cytokines in major depression. Biol
Psychiatry 2010;67:446–457.
4. Liu Y, Ho RCM, Mak A. Interleukin (IL)-6, tumour
necrosis factor alpha (TNF-a) and soluble interleukin-2
receptors (sIL-2R) are elevated in patients with major
depressive disorder: A meta-analysis and meta-regression.
J Affect Disord 2012;139:230–239.
5. Maes M, Scharpe S, Meltzer HY, et al. Increased
neopterin and interferon-gamma secretion and lower
availability of L-tryptophan in major depression: Further
evidence for an immune response. Psychiatry Res
1994;54:143–160.
6. Raison CL, Capuron L, Miller AH. Cytokines sing the
blues: Inflammation and the pathogenesis of depression.
Trends Immunol 2006;27:24–31.
7. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as
a precipitant of depressive illness: Animal and human
studies. Curr Pharm Des 2005;11:963–972.
8. Wichers M, Maes M. The
psychoneuroimmuno-pathophysiology of
cytokine-induced depression in humans. Int J
Neuropsychopharmacol 2002;5:375–388.
Figure 2 Serum levels of interleukin-6 (IL-6), tumor necrosis factor (TNF), interferon gamma (IFN-c), and IL-10 in alcohol-use disorder patients reporting no
history of lifetime major depression (no MD, n = 96) or reporting a lifetime history of major depression (MD, n = 80) by drinking frequency, intensity,
alcohol abuse or dependence and abstinence duration. Data are presented as medians. Significant differences in the no MD and MD groups by the
severity of alcohol-use features, calculated by Mann–Whitney U-test, are indicated by asterisk marks (*P < 0.05, **P < 0.01).
ª 2014 John Wiley & Sons Ltd CNS Neuroscience & Therapeutics 20 (2014) 898–904 903
S.P. Neupane et al. Cytokines in AUD-MD Comorbidity
9. Motivala SJ, Sarfatti A, Olmos L, Irwin MR.
Inflammatory markers and sleep disturbance in major
depression. Psychosom Med 2005;67:187–194.
10. Raedler TJ. Inflammatory mechanisms in major
depressive disorder. Curr Opin Psychiatry 2011;24:519–
525.
11. Sullivan LE, Fiellin DA, O’Connor PG. The prevalence
and impact of alcohol problems in major depression: A
systematic review. Am J Med 2005;118:330–341.
12. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and
co-occurrence of substance use disorders and independent
mood and anxiety disorders: Results from the National
Epidemiologic Survey on Alcohol and Related Conditions.
Arch Gen Psychiatry 2004;61:807–816.
13. Lynskey MT. The comorbidity of alcohol dependence and
affective disorders: Treatment implications. Drug Alcohol
Depend 1998;52:201–209.
14. Swendsen JD, Merikangas KR, Canino GJ, Kessler RC,
Rubio-Stipec M, Angst J. The comorbidity of alcoholism
with anxiety and depressive disorders in four geographic
communities. Compr Psychiatry 1998;39:176–184.
15. Neupane SP, Bramness JG. Prevalence and correlates of
major depression among Nepalese patients in treatment
for alcohol-use disorders. Drug Alcohol Rev 2013;32:170–
177.
16. Goral J, Karavitis J, Kovacs EJ. Exposure-dependent
effects of ethanol on the innate immune system. Alcohol
2008;42:237–247.
17. Crews FT, Bechara R, Brown LA, et al. Cytokines and
alcohol. Alcohol Clin Exp Res 2006;30:720–730.
18. Szabo G, Mandrekar P. A recent perspective on alcohol,
immunity, and host defense. Alcohol Clin Exp Res
2009;33:220–232.
19. Achur RN, Freeman WM, Vrana KE. Circulating
cytokines as biomarkers of alcohol abuse and alcoholism.
J Neuroimmune Pharmacol 2010;5:83–91.
20. Schleifer SJ, Keller SE, Czaja S. Major depression and
immunity in alcohol-dependent persons. Brain Behav
Immun 2006;20:80–91.
21. Irwin M, Miller C. Decreased natural killer cell responses
and altered interleukin-6 and interleukin-10 production
in alcoholism: An interaction between alcohol
dependence and African-American ethnicity. Alcohol Clin
Exp Res 2000;24:560–569.
22. Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Plasma
cytokine levels in a population-based study: Relation to
age and ethnicity. J Gerontol A Biol Sci Med Sci
2010;65:429–433.
23. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG.
The alcohol use disorders identification test: Guidelines for use in
primary care, 2nd edn. Zeneva: World Health
Organization, 2001.
24. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi
L. The Hopkins Symptom Checklist (HSCL): A self-report
symptom inventory. Behav Sci 1974;19:1–15.
25. Carey KB, Carey MP, Chandra PS. Psychometric
evaluation of the alcohol use disorders identification test
and short drug abuse screening test with psychiatric
patients in India. J Clin Psychiatry 2003;64:767–774.
26. Van Ommeren M, Sharma B, Thopa S, et al. Preparing
instruments for transcultural research: Use of the
translation monitoring form with Nepali-speaking
Bhutanese refugees. Transcult Psychiatry 1999;36:285–301.
27. Wittchen HU. Reliability and validity studies of the WHO–
Composite International Diagnostic Interview (CIDI): A
critical review. J Psychiatr Res 1994;28:57–84.
28. Kelley KW, Dantzer R. Alcoholism and inflammation:
Neuroimmunology of behavioral and mood disorders.
Brain Behav Immun 2011;25(suppl):13–20.
29. Halaris A. Inflammation, heart disease, and depression.
Curr Psychiatry Rep 2013;15:1–9.
30. Gold SM, Irwin MR. Depression and immunity:
Inflammation and depressive symptoms in multiple
sclerosis. Immunol Allergy Clin North Am 2009;29:309–320.
31. Jehn CF, Kuehnhardt D, Bartholomae A, et al.
Biomarkers of depression in cancer patients. Cancer
2006;107:2723–2729.
32. Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns
in fibromyalgia and their correlation with clinical
manifestations. Clin Exp Rheumatol 2007;25:225–230.
33. Cook RT. Alcohol abuse, alcoholism, and damage to the
immune system–a review. Alcohol Clin Exp Res
1998;22:1927–1942.
34. Copeland WE, Shanahan L, Worthman C, Angold A,
Costello EJ. Cumulative depression episodes predict later
C-reactive protein levels: A prospective analysis. Biol
Psychiatry 2012;71:15–21.
35. Badawy AA, Doughrty DM, Marsh-Richard DM, Steptoe
A. Activation of liver tryptophan pyrrolase mediates the
decrease in tryptophan availability to the brain after acute
alcohol consumption by normal subjects. Alcohol Alcohol
2009;44:267–271.
36. Gao B. Hepatoprotective and anti-inflammatory cytokines
in alcoholic liver disease. J Gastroenterol Hepatol
2012;27:89–93.
37. Munzer A, Sack U, Mergl R, et al. Impact of
antidepressants on cytokine production of depressed
patients in vitro. Toxins (Basel) 2013;5:2227–2240.
904 CNS Neuroscience & Therapeutics 20 (2014) 898–904 ª 2014 John Wiley & Sons Ltd
Cytokines in AUD-MD Comorbidity S.P. Neupane et al.
